Education
About Us
Working with TipRanks
Follow Us
Bicara Therapeutics Inc. (BCAX)
:BCAX
RESEARCH TOOLSreports
Total Valuation
Bicara Therapeutics Inc. has a market cap or net worth of $591.17M. The enterprise value is $1.21B.
Market Cap$591.17M
Enterprise Value$1.21B
Share Statistics
Bicara Therapeutics Inc. has 54,536,217 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding54,536,217
Owned by Insiders37.31%
Owned by Institutions0.01%
Financial Efficiency
Bicara Therapeutics Inc.’s return on equity (ROE) is -0.14 and return on invested capital (ROIC) is -16.77%.
Return on Equity (ROE)-0.14
Return on Assets (ROA)-0.13
Return on Invested Capital (ROIC)-16.77%
Return on Capital Employed (ROCE)-0.17
Revenue Per Employee0.00
Profits Per Employee-1.24M
Employee Count55
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Bicara Therapeutics Inc. is -43.05. Bicara Therapeutics Inc.’s PEG ratio is 0.00.
PE Ratio-43.05
PS Ratio0.00
PB Ratio-12.26
Price to Fair Value5.95
Price to FCF-37.55
Price to Operating Cash Flow-37.78
PEG Ratio0.00
Income Statement
In the last 12 months, Bicara Therapeutics Inc. had revenue of 0.00 and earned -68.00M in profits. Earnings per share was -0.40.
Revenue0.00
Gross Profit0.00
Operating Income-82.39M
Pretax Income-67.81M
Net Income-68.00M
EBITDA-67.75M
Earnings Per Share (EPS)-0.40
Cash Flow
In the last 12 months, operating cash flow was -89.11M and capital expenditures -59.50K, giving a free cash flow of -89.17M billion.
Operating Cash Flow-89.11M
Free Cash Flow-89.17M
Free Cash Flow per Share-1.64
Dividends & Yields
Bicara Therapeutics Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.78
52-Week Price Change-57.34%
50-Day Moving Average12.40
200-Day Moving Average―
Relative Strength Index (RSI)44.07
Average Volume (3m)1.11M
Important Dates
Bicara Therapeutics Inc. upcoming earnings date is May 13, 2025, TBA Not Confirmed.
Last Earnings DateMar 27, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Bicara Therapeutics Inc. as a current ratio of 27.93, with Debt / Equity ratio of 0.00%
Current Ratio27.93
Quick Ratio27.93
Debt to Market Cap<0.01
Net Debt to EBITDA7.22
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Bicara Therapeutics Inc. has paid 187.00K in taxes.
Income Tax187.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Bicara Therapeutics Inc. EV to EBITDA ratio is -35.99, with an EV/FCF ratio of -32.59.
EV to Sales0.00
EV to EBITDA-35.99
EV to Free Cash Flow-32.59
EV to Operating Cash Flow-32.62
Balance Sheet
Bicara Therapeutics Inc. has $462.06M in cash and marketable securities with $591.00K in debt, giving a net cash position of -$461.47M billion.
Cash & Marketable Securities$462.06M
Total Debt$591.00K
Net Cash-$461.47M
Net Cash Per Share-$8.46
Tangible Book Value Per Share$2.93
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Bicara Therapeutics Inc. is $32.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$32.60
Price Target Upside200.74% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast―